Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
Related Questions
Would you ever consider oral doxycycline for treatment of either gram-negative or gram-positive uncomplicated bacteremia?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?
How do you integrate next-generation sequencing with traditional culture methods to improve the identification of fungal pathogens, especially in cases where routine cultures are negative when evaluating suspected prosthetic joint infections?
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
For patients with spinal hardware infections, in what circumstances do you recommend 12 weeks over 6 weeks of antimicrobial therapy?
How would you approach treatment duration for patients with persistent candida species fungemia with a history of a prosthetic heart valve but negative TEE/CT PET and no other identifiable source of infection?
How would you approach treatment in a patient with refractory Coccidioidal meningitis who has previously been treated with IV amphotericin B?
Have you incorporated the use of linezolid in lieu of vancomycin plus clindamycin for empiric treatment of necrotizing fasciitis?
Is there any utility to trending Histoplasma serology titers to guide duration of therapy or treatment response for pulmonary histoplasmosis with negative urine antigen?
What is your approach to treatment of patients with fulminant C difficile infection who required ileostomy creation or colectomy?
